Immuno-oncology firm Candel cuts its workforce in half


A 24-year-old biotech that made its way to the Nasdaq in 2021 is drastically cutting its workforce as it scales back a cancer drug.

Previous Spirit Airlines CEO appointed to board of publicly traded health care company
Next Allegheny County, UPMC and Partner4Work collaborate on workforce development program